Glaukos Co. (NYSE:GKOS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Glaukos Co. (NYSE:GKOS) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, ten have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $147.75.

GKOS has been the subject of several recent research reports. Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and upped their target price for the company from $132.00 to $162.00 in a research report on Wednesday, December 11th. Stephens raised Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. lifted their price objective on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Wells Fargo & Company increased their target price on shares of Glaukos from $145.00 to $153.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Finally, UBS Group started coverage on Glaukos in a research note on Friday, December 6th. They set a “buy” rating and a $182.00 price objective on the stock.

Insider Activity

In other news, COO Joseph E. Gilliam sold 3,328 shares of Glaukos stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $149.85, for a total value of $498,700.80. Following the completion of the transaction, the chief operating officer now owns 102,169 shares of the company’s stock, valued at $15,310,024.65. This trade represents a 3.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gilbert H. Kliman sold 10,000 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the completion of the sale, the director now directly owns 32,336 shares in the company, valued at approximately $4,859,454.08. The trade was a 23.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 17,603 shares of company stock worth $2,605,678 over the last ninety days. Insiders own 6.40% of the company’s stock.

Institutional Trading of Glaukos

Several institutional investors and hedge funds have recently bought and sold shares of the business. Values First Advisors Inc. bought a new stake in shares of Glaukos during the third quarter worth approximately $25,000. Harvest Fund Management Co. Ltd increased its position in Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after buying an additional 860 shares during the period. KBC Group NV lifted its holdings in shares of Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 201 shares in the last quarter. Zhang Financial LLC acquired a new position in shares of Glaukos in the fourth quarter valued at about $221,000. Finally, EWA LLC bought a new position in Glaukos during the third quarter worth about $209,000. Institutional investors own 99.04% of the company’s stock.

Glaukos Stock Up 0.9 %

Shares of GKOS opened at $161.55 on Friday. The business’s fifty day moving average price is $146.86 and its two-hundred day moving average price is $134.31. The firm has a market capitalization of $8.91 billion, a price-to-earnings ratio of -53.49 and a beta of 1.04. Glaukos has a 52 week low of $83.90 and a 52 week high of $163.71. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm had revenue of $96.70 million during the quarter, compared to analysts’ expectations of $91.50 million. During the same period in the previous year, the business posted ($0.50) EPS. The company’s quarterly revenue was up 23.9% compared to the same quarter last year. On average, analysts predict that Glaukos will post -1.89 earnings per share for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.